Clinical trial
Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis
NCT00202410 · S. Andrea Hospital, Other · Completed
Key facts
| NCT number | NCT00202410 |
|---|---|
| Title | Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis |
| Official title | Phase 2-3 Use of Bacille Calmette-Guèrin (BCG) Vaccine in Patients With a First Clinical Demyelinating Episode: a Multicenter, Randomized, Single Blind Study. |
| Lead sponsor | S. Andrea Hospital, Other |
| Collaborators | Italian Multiple Sclerosis Foundation Istituto Superiore di Sanità |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Biological, Other |
| Interventions | Bacille of Calmette-Guerin, placebo |
| Enrollment | 80 |
| Start date | Nov 1, 2001 |
| Primary completion | Sep 1, 2007 |
| Completion | Apr 1, 2008 |
| First posted | Sep 20, 2005 |
| Last update posted | May 19, 2011 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: